1.74
+2.96%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Evotec SE ADR
Its shares trade under the ticker EVO. It has been listed since 4 December 2009. In the fiscal year to 31 December 2025, it reported revenue of $882.3m and a net loss of $115.8m. At that date it held total assets of $2.07bn and shareholders' equity of $947.6m.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Dec 2009
- Employees
- 4,553
- Website
- evotec.com ↗
- Head office
- ESSENER BOGEN 7, HAMBURG, 22419
- Incorporated in
- 2M
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Evotec SE operates in the United States, Germany, France, the United Kingdom, and Switzerland.
- The company employs 4553 people across its international drug discovery operations.
- Collaborations include Mass General Brigham and Joslin Diabetes Center for cardiometabolic diseases.
Weaknesses
- The company operates in two segments: Shared R&D and Evotec Biologics.
- Development focuses on oncology, autoimmune, cancer, diabetes, and heart failure diseases.
- Research also covers central nervous system and cardiometabolic diseases globally.
Opportunities
- Partnerships with Novo Nordisk support cell therapy development initiatives.
- University of Oxford and German Cancer Research Center enhance research capabilities.
- Harvard and Yale universities provide strong academic collaboration frameworks.
Threats
- Competition exists in the global health care sector for drug discovery.
- Regulatory changes in the United States may impact listing operations.
- Market volatility affects the financial stability of biotechnology partnerships.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.